torsten dreier - Argenx NV Chief Development Officer
| ARGX Stock | USD 360.23 1.82 0.51% |
Executive
Dr. Torsten Dreier is the Chief Development Officer of argenx SE since May 2008. He was developing antibodies for more than 20 years and progressed six antibody products from preclinical research into clinical trials. Prior to joining argenx, he was Director of Therapeutic Drug Development and Senior Director Preclinical Development at Ablynx NV, with overall responsibility for pharmacology, toxicology, bioanalytics and CMC as well as early clinical development. Between 19972003, Dr. Dreier worked as Director Preclinical Development at Micromet AG in Munich, Germany, on the preclinical characterization of recombinant antibodies and BiTEs. He holds a PhD in Biochemistry from the University of Tbingen, Germany. In 1995, he joined the group of Prof. Ralf A. Reisfeld at the Scripps Research Institute in La Jolla, CA as a postdoctoral researcher and extended his knowhow in immunology with his work on immunocytokines, recombinant antibodies and cytokines. since 2008.
| Age | 52 |
| Tenure | 16 years |
| Professional Marks | Ph.D |
| Address | Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB |
| Phone | 31 10 703 8441 |
| Web | https://www.argenx.com |
Argenx NV Management Efficiency
The company has return on total asset (ROA) of (0.0685) % which means that it has lost $0.0685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0854) %, meaning that it created substantial loss on money invested by shareholders. Argenx NV's management efficiency ratios could be used to measure how well Argenx NV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Argenx NV's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 439.7 M in 2024, whereas Other Current Assets are likely to drop slightly above 99.6 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Indrani JD | Alnylam Pharmaceuticals | 51 | |
| Liza Heapes | BeiGene | N/A | |
| Nyssa Noyola | Ascendis Pharma AS | N/A | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
| Evan MBA | Alnylam Pharmaceuticals | N/A | |
| Tolga MBA | Alnylam Pharmaceuticals | 51 | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Joanne Choi | Legend BiotechCorp | N/A | |
| James JD | Legend BiotechCorp | N/A | |
| Emil MD | Terns Pharmaceuticals | 43 | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| Yang Ji | BeiGene | N/A | |
| Christopher CFA | Travere Therapeutics | 39 | |
| Hing Chau | BeiGene | 43 | |
| Jason Radford | BeiGene | 42 | |
| Jonathan Leff | Ascendis Pharma AS | 57 | |
| Steven Axon | Apellis Pharmaceuticals | N/A | |
| Janet Graesser | VaxcyteInc | N/A | |
| Alan Kick | Legend BiotechCorp | N/A | |
| Pr MD | Apellis Pharmaceuticals | N/A | |
| Casey Logan | Travere Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.0854 | ||||
| Return On Asset | -0.0685 |
argenx NV ADR Leadership Team
Elected by the shareholders, the Argenx NV's board of directors comprises two types of representatives: Argenx NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Argenx. The board's role is to monitor Argenx NV's management team and ensure that shareholders' interests are well served. Argenx NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Argenx NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karen Massey, Chief Officer | ||
| Peter Verhaeghe, Chairman of the Supervisory Board | ||
| Torsten Dreier, Chief Development Officer | ||
| Werner Lanthaler, Member of the Supervisory Board | ||
| Beth DelGiacco, VP Relations | ||
| Filip Borgions, VP Operations | ||
| Debbie Allen, Senior Director, Business Development | ||
| Harrold Berlingen, Member of the Supervisory Board | ||
| Arjen MSc, Vice Strategy | ||
| Eric Castaldi, CFO | ||
| Joseph Bethizy, Non-Executive Member of the Board | ||
| Michael Saunders, Senior Director Targets & Programs | ||
| Karl Gubitz, Chief Officer | ||
| Rebecca McLeod, Vice President Marketing | ||
| Jacobus Rasser, IP Counsel | ||
| Malini Moorthy, General Counsel | ||
| John Koning, Member of the Supervisory Board | ||
| Peter Ulrichts, Chief Officer | ||
| Hans Haard, Chief Scientific Officer | ||
| Pr Ir, CoFounder Officer | ||
| Nicolas Leupin, MD, MBA, Chief Medical Officer | ||
| Christina Takke, Member of the Supervisory Board | ||
| Luc Rompaey, VP Translational Medicine | ||
| Dirk Beeusaert, General Counsel | ||
| EMBA MBA, CEO Director | ||
| Trevor Leighton, Vice President Market Access | ||
| Bruno Montanari, Member of the Supervisory Board | ||
| Alain Thibault, Chief Medical Officer | ||
| Luc Truyen, Chief Officer | ||
| David Lacey, Member of the Supervisory Board | ||
| Michael Sheffery, Member of the Supervisory Board | ||
| A Rosenberg, Non-Executive Director | ||
| Keith Woods, Chief Officer | ||
| Tim Hauwermeiren, CEO | ||
| Pamela Klein, Non-Executive Member of the Board | ||
| David MD, Advisor | ||
| Andria Wilk, Global Quality | ||
| Marc Schorpion, Global Resources |
Argenx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Argenx NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0854 | ||||
| Return On Asset | -0.0685 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.33) % | ||||
| Current Valuation | 18.09 B | ||||
| Shares Outstanding | 59.43 M | ||||
| Shares Owned By Institutions | 55.77 % | ||||
| Number Of Shares Shorted | 1.2 M | ||||
| Price To Earning | 5.54 X | ||||
| Price To Book | 5.47 X |
Pair Trading with Argenx NV
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Argenx NV position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Argenx NV will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Argenx NV could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Argenx NV when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Argenx NV - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling argenx NV ADR to buy it.
The correlation of Argenx NV is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Argenx NV moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if argenx NV ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Argenx NV can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in argenx NV ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the argenx NV ADR information on this page should be used as a complementary analysis to other Argenx NV's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Argenx Stock analysis
When running Argenx NV's price analysis, check to measure Argenx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argenx NV is operating at the current time. Most of Argenx NV's value examination focuses on studying past and present price action to predict the probability of Argenx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argenx NV's price. Additionally, you may evaluate how the addition of Argenx NV to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Argenx NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Argenx NV. If investors know Argenx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Argenx NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.16) | Revenue Per Share 0.8876 | Quarterly Revenue Growth 1.349 | Return On Assets (0.07) | Return On Equity (0.09) |
The market value of argenx NV ADR is measured differently than its book value, which is the value of Argenx that is recorded on the company's balance sheet. Investors also form their own opinion of Argenx NV's value that differs from its market value or its book value, called intrinsic value, which is Argenx NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Argenx NV's market value can be influenced by many factors that don't directly affect Argenx NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Argenx NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Argenx NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Argenx NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.